Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interfant-21 for KMT2A-rearranged infant ALL/MPAL
NL-OMON51982Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jan 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Event-free survival. Started Jan 2023; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON51982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51982.